Healthcare / BiotechnologyShenzhen
$6.29
-0.37 (-5.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $125.9M · quality 72.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.4%
↓Gross Margin
32.4%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-60.2%
FCF CAGR
-68.8%
FCF margin
10.6%
FCF / Net income
-0.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $757.7M · net income $-744.4M · FCF $80.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $757.7M | $757.7M | $853.0M | $1.18B | $12.05B |
| Net Income | $-744.4M | $-744.4M | $-925.2M | $104.7M | $5.41B |
| EBITDA | $-453.1M | $-453.1M | $-711.1M | $480.7M | $6.63B |
| EPS | -0.53 | -0.53 | -0.66 | 0.07 | 3.86 |
| Gross Margin | 32.4% | 32.4% | 37.5% | 50.5% | 72.8% |
| Operating Margin | -39.2% | -39.2% | -26.9% | 4.8% | 56.6% |
| Net Margin | -98.2% | -98.2% | -108.5% | 8.9% | 44.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 |
| Current Ratio | 2.98 | 2.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $80.5M | $80.5M | $125.9M | $207.3M | $2.65B |
| Returns | |||||
| ROE | -10.4% | -10.4% | -11.7% | 1.2% | 47.9% |
| Valuation | |||||
| P/E | — | — | — | 137.86 | 4.12 |
| EV/EBITDA | — | — | — | 28.70 | 3.01 |
| P/B | 1.24 | 1.24 | 0.96 | 1.62 | 1.97 |
| Growth & Yield | |||||
| Revenue Growth | -11.2% | -11.2% | -27.8% | -90.2% | — |
| EPS Growth | 19.7% | 19.7% | -1042.9% | -98.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.66 → -0.53
Residual
+10.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.